what to eat on retatrutide Diet: Why Eating Healthy Stalls Results Hard truth: Retatrutide won't fix

PubMed Lanca S, Alves A, Vieira AI, et al

Clinical trial results for retatrutide have exceeded even the high expectations set by tirzepatide, with Phase 2 data published in the New England Journal of Medicine in 2023 demonstrating weight loss approaching 24-25% of baseline body weight over 48 weeks in some dose groups - weight reductions comparable to those achieved with bariatric surgery and substantially exceeding pharmacological obesity treatments available just a few years ago

The SURMOUNT-1 trial formally assessed weight loss of tirzepatide against placebo in obesity

Sorensen, S

Tirzepatide is also contraindicated in multiple endocrine neoplasia syndrome type-2 (MEN-2)